Phaseline

Targets › GPCS

GPCS: drug programs, companies and trials

2 programs from 2 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on GPCS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CARsgen TherapeuticsCT011 CAR-GPC3 T Cells Injection
Anti-GPC3 CAR-T cell therapy
GPCSPhase 1HCCDec 2026
Baylor College of MedicineCARE T cells (15.21.GPC3-CAR T cells)
Glypican-3-specific CAR T cells expressing interleukin-15 and interleukin-21
GPC3, GPCSPhase 1Liver Cancer; Hepatoblastoma; Glioblastoma Multiforme of BrainAug 2027

Conditions

Liver Cancer (1) Hepatoblastoma (1) Glioblastoma Multiforme of Brain (1) HCC (1)

Modalities

other (2)

Companies

Baylor College of Medicine (1) CARsgen Therapeutics (1)

Related targets

GPC3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.